Featured Research

from universities, journals, and other organizations

Personalized Medicine: Moving Forward Slowly But Surely

Date:
February 12, 2008
Source:
American Chemical Society
Summary:
With its promises of more effective, low-cost therapies for cancer, heart disease, Alzheimer's and other medical conditions, personalized medicine is moving forward but at a slow pace that's not keeping up with its high expectations. Personalized medicine, the practice of catering medical therapies to the specific genetic and disease profiles of patients, represents a major shift from the one-size-fits-all model of traditional medicine.

With its promises of more effective, low-cost therapies for cancer, heart disease, Alzheimer's and other medical conditions, personalized medicine is moving forward but at a slow pace that's not keeping up with its high expectations, according to the article "Personalized Medicine" scheduled for the Feb. 11 issue of Chemical & Engineering News.

In the magazine's cover story, C&EN Senior Editor Rick Mullin notes that personalized medicine, the practice of catering medical therapies to the specific genetic and disease profiles of patients, represents a major shift from the one-size-fits-all model of traditional medicine. Despite its promise, researchers have had difficulty translating new genetic knowledge into effective therapies.

But fueled by new research tools and new genetic information, the field is silently moving forward. Notable successes include the development of Herceptin, a targeted therapy for breast cancer, and Gleevec, a treatment for lung cancer.

Other targeted therapies are in the pipeline. "We are at a kind of crossroads where we have developed a large number of new agents with pharmacologically sound activities," C&EN quotes one researcher. "But clearly, to hit the home run, you have to match the right drug to the right patient. It's easier said than done."


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "Personalized Medicine: Moving Forward Slowly But Surely." ScienceDaily. ScienceDaily, 12 February 2008. <www.sciencedaily.com/releases/2008/02/080211094056.htm>.
American Chemical Society. (2008, February 12). Personalized Medicine: Moving Forward Slowly But Surely. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2008/02/080211094056.htm
American Chemical Society. "Personalized Medicine: Moving Forward Slowly But Surely." ScienceDaily. www.sciencedaily.com/releases/2008/02/080211094056.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins